Use of cytomegalovirus immune globulin and ganciclovir for the prevention of cytomegalovirus disease in lung transplantation

Transplant Infectious Disease

Volumn 3, Issue SUPPL. 2, 2001, Pages 49-56

  Zamora, M R ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

CMV IGIV; Cytomegalovirus; Ganciclovir; Lung transplantation

Indexed keywords

CYTOMEGALOVIRUS ANTIBODY; GANCICLOVIR;

ARTICLE; ASPERGILLUS; BACTERIAL SUPERINFECTION; BRONCHIOLITIS; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; HUMAN; HYPOGAMMAGLOBULINEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION CONTROL; INFECTION RATE; INFECTION RISK; LUNG TRANSPLANTATION; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT OUTCOME;

AGAMMAGLOBULINEMIA; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; GANCICLOVIR; GRAFT SURVIVAL; HUMANS; IMMUNOGLOBULINS; LUNG TRANSPLANTATION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0035691004     PISSN: 13982273     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3062.2001.00010.x     Document Type: Article

References (26)

1. Advances in understanding cytomegalovirus infection after transplantation
2. The cost impact of cytomegalovirus disease in renal transplant recipients
3. Use of the human cytomegalovirus (HCMV) antigenemia assay for diagnosis and monitoring of HCMV infections and detection of antiviral drug resistance in the immunocompromised
4. Detection of human cytomegalovirus antigenemia: A rapid diagnostic technique for predicting cytomegalovirus infection/pneumonitis in lung and heart transplant recipients
5. Detection of CMV pneumonitis after lung transplantation using PCR of DNA from bronchoalveolar lavage cells
6. Increased human cytomegalovirus (HCMV) DNA load in peripheral blood leukocytes after lung transplantation correlates with HCMV pneumonia
7. Comparison of PCR, antigenemia assay and rapid blood culture for detection and prevention of cytomegalovirus disease after lung transplantation
8. Evaluation of CMV viral load using TaqMan CMV quantitative PCR and comparison with CMV antigenemia in heart and lung transplant recipients
9. Evaluation of the AMPLICOR CMV, COBAS AMPLICOR CMV monitor, and antigenemia assay for cytomegalovirus disease
10. Randomized trial of daily versus three-times-weekly prophylactic ganciclovir after lung and heart-lung transplantation
11. Failure of prophylactic ganciclovir to prevent cytomegalovirus disease in recipients of lung transplant
12. Sequelac of cytomegalovirus pulmonary infections in lung allograft recipients
13. A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation
14. Efficacy of a 6-week prophylactic ganciclovir regimen and the role of serial cytomegalovirus antibody testing in lung transplant recipients
15. Impact of ganciclovir prophylaxis on heart-lung and lung transplant recipients
16. Prevention and treatment of cytomegalovirus disease in thoracic organ transplant patients: Evidence for a beneficial effect of hyperimmune globulin
17. Use of Cytomegalovirus hyperimmune globulin for the prevention of CMV disease in CMV seropositive lung transplant recipients
18. Cytomegalovirus immune globulin (CMVIG) in combination with ganciclovir provides cost-effective prophylaxis for CMV after lung transplantation
19. Comparison between CMV hyperimmune globulin and GCV for CMV prophylaxis in heart-lung and lung transplant recipients
20. Pre-emptive treatment for the prevention of cytomegalovirus disease: In lung and heart transplant recipients
21. Pre-emptive therapy with ganciclovir and cytomegalovirus immune globulin prevents CMV-associated acute and possibly chronic rejection following lung transplantation
22. The impact of ganciclovir-resistant cytomegalovirus infection after lung transplantation
23. Immunoglobulin abnormalities in renal transplant recipients
24. B-cell dysfunction and depletion using mycophenolate mofetil in a pediatric combined liver and kidney graft recipient
25. Hypogammaglobulinemia in lung transplant recipients
26. Monthly infusion of cytomegalovirus immune globulin (CMVIG) decreases the incidence of bacterial and fungal infections in the first year following lung transplantation